Zhiguang Lin
Shanghai, 200040, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Exosomal ANGPTL2 in cerebrospinal fluid as a novel prognostic biomarker for primary central nervous system lymphoma.
Journal: Frontiers in immunology
Published: September 05, 2025
Machine Learning-Enhanced Cerebrospinal Fluid N-Glycome for the Diagnosis and Prognosis of Primary Central Nervous System Lymphoma.
Journal: Journal of proteome research
Published: April 22, 2025
Metabolic pathway alterations in cerebrospinal fluid as diagnostic biomarkers for primary central nervous system lymphoma.
Journal: Clinica chimica acta; international journal of clinical chemistry
Published: August 14, 2024
Targeted multiplex validation of CSF proteomic biomarkers: implications for differentiation of PCNSL from tumor-free controls and other brain tumors.
Journal: Frontiers in immunology
Published: November 23, 2023
Specific KIR-HLA genotypes predict outcomes in refractory or relapsed primary central nervous system lymphoma.
Journal: Hematology (Amsterdam, Netherlands)
Published: August 07, 2023
High-throughput quantitation of amino acids and acylcarnitine in cerebrospinal fluid: identification of PCNSL biomarkers and potential metabolic messengers.
Journal: Frontiers in molecular biosciences
Published: July 11, 2023
Prognostic impact of peripheral natural killer cells in primary central nervous system lymphoma.
Journal: Frontiers in immunology
Published: March 21, 2023
Cerebrospinal fluid metabolic markers predict prognosis behavior of primary central nervous system lymphoma with high-dose methotrexate-based chemotherapeutic treatment.
Journal: Neuro-oncology advances
Published: March 07, 2023
Radiotherapy or chemotherapy: a real-world study of the first-time relapsed and refractory primary central nervous system lymphoma.
Journal: Frontiers in oncology
Published: November 15, 2022
Last Updated: 09/26/2026